Abstract

Sialic acid (NeuAc) is a major anion on endothelial cells (ECs) that regulates different biological processes including angiogenesis. NeuAc is present in the oligosaccharidic portion of integrins, receptors that interact with extracellular matrix components and growth factors regulating cell adhesion, migration, and proliferation. Tat is a cationic polypeptide that, once released by HIV-1(+) cells, accumulates in the extracellular matrix, promoting EC adhesion and proangiogenic activation by engaging α(v)β(3). By using two complementary approaches (NeuAc removal by neuraminidase or its masking by NeuAc-binding lectin from Maackia amurensis, MAA), we investigated the presence of NeuAc on endothelial α(v)β(3) and its role in Tat interaction, EC adhesion, and proangiogenic activation. α(v)β(3) immunoprecipitation with biotinylated MAA or Western blot analysis of neuraminidase-treated ECs demonstrated that NeuAc is associated with both the α(v) and the β(3) subunits. Surface plasmon resonance analysis demonstrated that the masking of α(v)β(3)-associated NeuAc by MAA prevents Tat/α(v)β(3) interaction. MAA and neuraminidase prevent α(v)β(3)-dependent EC adhesion to Tat, the consequent FAK and ERK1/2 phosphorylation, and EC proliferation, migration, and regeneration in a wound-healing assay. Finally, MAA inhibits Tat-induced neovascularization in the ex vivo human artery ring sprouting assay. The inhibitions are specific because the NeuAc-unrelated lectin from Ulex europaeus is ineffective on Tat. Also, MAA and neuraminidase affect only weakly integrin-dependent EC adhesion and proangiogenic activation by fibronectin. In conclusion, NeuAc is associated with endothelial α(v)β(3) and mediates Tat-dependent EC adhesion and proangiogenic activation. These data point to the possibility to target integrin glycosylation for the treatment of angiogenesis/AIDS-associated pathologies.

Highlights

  • HIV-1 Tat engages ␣v␤3, leading to endothelial cell (EC) proangiogenic activation

  • By using two complementary approaches (NeuAc removal by neuraminidase or its masking by NeuAcbinding lectin from Maackia amurensis, MAA), we investigated the presence of NeuAc on endothelial ␣v␤3 and its role in Tat interaction, EC adhesion, and proangiogenic activation. ␣v␤3 immunoprecipitation with biotinylated MAA or Western blot analysis of neuraminidase-treated ECs demonstrated that NeuAc is associated with both the ␣v and the ␤3 subunits

  • MTS Assay—Tat-adherent GM7373 ECs were treated with neuraminidase or lectins as described above and incubated for 24 or 48 h in Dulbecco’s modified minimum essential medium (DMEM), 0.4% fetal calf serum (FCS)

Read more

Summary

Background

Results: Sialic acid (NeuAc)-binding lectins and neuraminidase partially inhibit Tat/␣v␤3 interaction and consequent EC proangiogenic activation. Sialic acid (NeuAc) is a major anion on endothelial cells (ECs) that regulates different biological processes including angiogenesis. NeuAc is present in the oligosaccharidic portion of integrins, receptors that interact with extracellular matrix components and growth factors regulating cell adhesion, migration, and proliferation. NeuAc is associated with endothelial ␣v␤3 and mediates Tat-dependent EC adhesion and proangiogenic activation These data point to the possibility to target integrin glycosylation for the treatment of angiogenesis/AIDS-associated pathologies. Integrins are widely distributed receptors that interact with extracellular matrix components, growth factors, and microbial proteins regulating adhesion, migration, and proliferation of various normal and transformed cell types [22]. On the basis of what is described above, in this study, we decided to evaluate the presence of NeuAc on integrin ␣v␤3 expressed at the EC surface and to investigate its role in Tat engagement and consequent biological activities

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call